Status:
COMPLETED
Safety and Efficacy of AGN 203818 in Patients With Painful Diabetic Peripheral Neuropathy
Lead Sponsor:
Allergan
Conditions:
Diabetic Neuropathy, Painful
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This study will explore the safety and effectiveness of different doses of AGN 203818 in treating pain in patients with painful diabetic peripheral neuropathy
Eligibility Criteria
Inclusion
- Diagnosis of diabetic peripheral neuropathy
- Moderate to severe neuropathic pain
Exclusion
- Any other uncontrolled disease
- Pregnant or nursing females
Key Trial Info
Start Date :
October 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2007
Estimated Enrollment :
330 Patients enrolled
Trial Details
Trial ID
NCT00381719
Start Date
October 1 2006
End Date
November 1 2007
Last Update
January 7 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tacoma, Washington, United States